Randomized control trial on the efficacy of Limosilactobacillus reuteri ATCC PTA 4659 in reducing inflammatory markers in acute uncomplicated diverticulitis.
Journal
European journal of gastroenterology & hepatology
ISSN: 1473-5687
Titre abrégé: Eur J Gastroenterol Hepatol
Pays: England
ID NLM: 9000874
Informations de publication
Date de publication:
01 05 2022
01 05 2022
Historique:
pubmed:
20
1
2022
medline:
19
4
2022
entrez:
19
1
2022
Statut:
ppublish
Résumé
Recent guidelines suggest treating acute uncomplicated diverticulitis (AUD) without antibiotics. We tested the efficacy of Limosilactobacillus reuteri ATCC PTA 4659 in AUD. Primary outcome was the reduction of abdominal pain and inflammatory markers [C-reactive protein (C-RP) and calprotectin]. Secondary outcome was the reduction of hours of hospitalization. A double-blind, randomized controlled trial was conducted in 119 patients with AUD. The probiotic group (61 patients) was treated with fluids, bowel rest and L. reuteri/b.i.d. for 10 days. The placebo group (58 patients) was treated with the same therapy and placebo/b.i.d. for 10 days. All patients completed a daily visual analogue scale (VAS) for abdominal pain. Both groups showed a mean VAS score of 7 at enrolment and a reduction of 4 points after 3 days. C-RP value, after 72 h, decreased by 58.8% in the probiotic group and by only 40% in the placebo group (P < 0.05). Calprotectin levels, after 72 h, decreased by 17% in the probiotic group and by only 10.6% in the control group (P < 0.05). In the probiotic group, the hospitalization was done for 75.5 h compared to 83.5 in the placebo group. The supplementation with L. reuteri 4659 together with bowel rest and fluids significantly reduced both blood and faecal inflammatory markers compared to the placebo group.
Identifiants
pubmed: 35045564
doi: 10.1097/MEG.0000000000002342
pii: 00042737-202205000-00004
pmc: PMC9936969
doi:
Substances chimiques
Leukocyte L1 Antigen Complex
0
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
496-502Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Simpson J. Recent advances in diverticular disease. Curr Gastroenterol Rep 2004; 6: 417–422.
Colonic diverticular disease. Nat Rev Dis Primers 2020; 6: 21.
van Dijk ST, Rottier SJ, van Geloven AAW, Boermeester MA. Conservative treatment of acute colonic diverticulitis. Curr Infect Dis Rep 2017; 19: 44.
Blair NP, Germann E. Surgical management of acute sigmoid diverticulitis. Am J Surg 2002; 183: 525–528.
Salzman H, Lillie D. Diverticular disease: diagnosis and treatment. Am Fam Physician 2005; 72: 1229–1234.
Parks TG. Natural history of diverticular disease of the colon. Clin Gastroenterol 1975; 4: 53–69.
Kaiser AM, Jiang JK, Lake JP, Ault G, Artinyan A, Gonzalez-Ruiz C, et al. The management of complicated diverticulitis and the role of computed tomography. Am J Gastroenterol 2005; 100: 910–917.
Tursi A. Current and evolving concepts on the pathogenesis of diverticular disease. J Gastrointestin Liver Dis 2019; 28: 225–235.
Narula N, Marshall JK. Role of probiotics in management of diverticular disease. J Gastroenterol Hepatol 2010; 25: 1827–1830.
Lahner E, Bellisario C, Hassan C, Zullo A, Esposito G, Annibale B. Probiotics in the treatment of diverticular disease. A systematic review. J Gastrointestin Liver Dis 2016; 25: 79–86.
Swanson SM, Strate LL. Acute colonic diverticulitis. Ann Intern Med 2018; 168: ITC65–ITC80.
van de Wall BJ, Draaisma WA, van der Kaaij RT, Consten ECJ, Wiezer MJ, Broeders IAMJ. The value of inflammation markers and body temperature in acute diverticulitis. Colorectal Dis 2013; 15: 621–626.
Kechagias A, Sofianidis A, Zografos G, Leandros E, Alexakis N, Dervenis C. Index C-reactive protein predicts increased severity in acute sigmoid diverticulitis. Ther Clin Risk Manag 2018; 14: 1847–1853.
Ticinesi A, Nouvenne A, Corrente V, Tana C, Di Mario F, Meschi T. Diverticular disease: a gut microbiota perspective. J Gastrointestin Liver Dis 2019; 28: 327–337.
Fric P, Zavoral M. The effect of non-pathogenic Escherichia coli in symptomatic uncomplicated diverticular disease of the colon. Eur J Gastroenterol Hepatol 2003; 15:313–5.
Jones SL, Blikslager AT. Disorders of the gastrointestinal system. Equine Internal Medicine 2004;769–949.
Tursi A, Brandimarte G, Giorgetti GM, Elisei W. Mesalazine and/or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon: a prospective, randomized, open-label study. J Clin Gastroenterol 2006; 40: 312–316.
Tursi A, Brandimarte G, Elisei W, Giorgetti GM, Inchingolo CD, Aiello F. Faecal calprotectin in colonic diverticular disease: a case-control study. Int J Colorectal Dis 2009; 24: 49–55.